Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
 |
|
as soon as is submitted to ZB.
Omics: Potential role in early-phase drug development.
In: Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development. London: Springer, 2015. 189-222
The development of high-throughput omics technologies has nourished the hope to improve our understanding and treatment of the pathophysiology of globally increasing diseases such as type 2 diabetes and obesity. These technologies provide innovative tools that have the potential to truly revolutionize patient care. Technologies continue to propel the omics fields forward. However, translating research discovery into routine clinical applications use is a complex process not only from scientific prospective but also from ethical, political, and logistic points of view. Particularly the implementation of omics-based tests requires changes in fundamental processes of regulation, reimbursement, and clinical practice. Altogether, developments in the field of omics technologies hold great promise to optimize patient care and improve outcomes and eventually lead to new tests that are well integrated in routine medical care.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Edited volume or book chapter
Editors
Krentz, A.J.* ; Heinemann, L.* ; Hompesch, M.*
Keywords
Genomics; Epigenomics; Transcriptomics; Proteomics; Metabolomics; Microarray; Sequencing; Disease prediction; Pharmacogenomics; Personalized medicine
e-ISSN
978-1-4471-4920-0
ISBN
978-1-4471-4919-4
Book Volume Title
Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development
Quellenangaben
Pages: 189-222
Publisher
Springer
Publishing Place
London
Non-patent literature
Publications